정규장
Log in Sign up
ENSC
ENSC
Ensysce Biosciences Inc
7월 28일 1:05 PM ET (한국 7/29 02:05)
$0.26
+0.00 +0.08%

엔시스 바이오사이언시스(ENSC) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$4M
스몰캡
P/E
-
배당수익률
없음
52주 위치
1%
저점 +14% · 고점 -90%
애널리스트
적극 매수
C
Fundamental health
vs. 방어주 초소형주· based on 2 axes
수익성
산출 불가 (적자)
성장
Top 33%
밸류에이션
데이터 부족
재무 안정
Top 85%
Index -P/E -EPS (ttm) -3.35Insider Own 0.07%Shs Outstand 15.4MPerf Week -3%
Market Cap 0.00BForward P/E -EPS next Y 92.81%Insider Trans -Shs Float 15.4MPerf Month -7.56%
Enterprise Value 0.00BPEG -EPS next Q -0.5Inst Own 3.17%Short Float 2.63%Perf Quarter -36.84%
Income -0.01BP/S 0.85EPS this Y 61.56%Inst Trans -0.15%Short Ratio 0.16Perf Half Y -69.55%
Sales 0.00BP/B -EPS next 5Y -ROA -347.7%Short Interest 0.40MPerf YTD -71.57%
Book/sh -0.04P/C 5.36EPS past 3/5Y 87.61% -ROE -870.19%52W High -90.49% ($2.75)Perf Year -88.32%
Cash/sh 0.05P/FCF -Sales past 3/5Y 26.16% 5.21%ROIC -52W Low 13.74% ($0.23)Perf 3Y -99.17%
Dividend Est. -EV/EBITDA -EPS Y/Y TTM 47.35%Gross Margin -Volatility(W/M) 8.94% 8.67%Perf 5Y -100%
Dividend TTM -EV/Sales 0.67Sales Y/Y TTM -24.36%Oper. Margin -251.4%ATR (14) 0.02Perf 10Y -
Dividend Ex-Date -Quick Ratio 0.71EPS Q/Q 62.55%Profit Margin -250.36%RSI (14) 41.79Recom 1
Dividend Gr. 3/5Y -Current Ratio 0.71Sales Q/Q -27.18%SMA20 -6.9% ($0.28)Beta 0.84Target Price $16.45
Payout -Debt/Eq -Earnings 2026/05/18SMA50 -7.02% ($0.28)Rel Volume 0.09Prev Close $0.26
Employees 10LT Debt/Eq -EPS/Sales Surpr. 28.77% -47.37%SMA200 -69.69% ($0.86)Avg Volume(3M) 2.56MPrice $0.26
IPO 2018/2/26Option/Short No/YesTrades 398Volume 223,729Change 0.08%
Quarterly earnings trend SEC filings · USD
24.6
24.9
24.12*
25.3
25.6
25.9
25.12*
26.3
Revenue Net income 최근 분기: 매출 $1M (YoY -27%) · 순이익 $-4M (YoY -83%)
* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Ensysce Biosciences Inc (ENSC) Investment Analysis

What kind of company is Ensysce Biosciences Inc?

엔시스 바이오사이언시스(ENSC) 방어주
Healthcare · Biotechnology
Small-Cap — Low Volume, High Volatility

💊 This is a clinical-stage pharmaceutical company developing next-generation painkillers with abuse-deterrent technology. It is researching new drug candidates designed to lower the abuse risk of opioids such as oxycodone, using its trypsin-activated TAAP platform and its overdose-prevention MPAR platform. The company has no commercialized products yet and remains a very small biotech that relies on its clinical-stage pipeline.

Learn more about Ensysce Biosciences Inc →
Market Cap
$0.0B
Approx. KRW 0.0 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank5716
Employees10people
IPO2018/02/26
Current Price$0.26 ≈ 356원
NASD · USA

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 18일 (월) · 장 마감 후 EPS +28.8% 매출 -47.4%
🔔 Earnings release 2026년 3월 26일 (목) · 장 마감 후 EPS +40.5% 매출 +277.7%

Is it profitable?

Profitability weak
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
-251.4%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Net Margin
Share of revenue left after taxes and interest are paid
-250.4%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROE
Annual return earned on shareholders' equity (15%+ is strong)
-870.2%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROA
Annual earnings relative to total company assets
-347.7%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Financial health — Debt & liquidity burden
Current Ratio
Liquid assets available to cover liabilities due within a year
0.71
✓ 매우 부진
My positionBottom 5%
Low range Average High range
Biotechnology Median 5.75
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
0.71
✓ 평균
My positionMid-range
Low range Average High range
Biotechnology Median 5.47
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Positive Outlook
Price targets, growth, and valuation are favorable
애널리스트 목표가
$16.45
현재가 대비 +6226.9%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
내년 EPS 예상 성장률
+92.8%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Reliability
Beat estimates in 2 of the last 2 quarters
2
예상 상회
0
예상 부합
0
예상 하회
100%
상회 비율
+34.6%
평균 서프라이즈
2026.05.18
상회
+28.8%
2026.03.26
상회
+40.5%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Strong Growth
Above the industry average, both historically and going forward
Healthy, Balanced Growth EPS and revenue are both growing steadily — a sustainable growth profile
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+61.6%
양호
My positionMid-range
Low range Average High range
방어주 초소형주 Median 21.2% · Top 28%
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+92.8%
우수
My positionTop 25%
Low range Average High range
방어주 초소형주 Median 14.5% · Top 21%
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+87.6%
우수
My positionTop 25%
Low range Average High range
방어주 초소형주 Median 30.0% · Top 6%
Past 5-Year Revenue
How much revenue grew over the past 5 years
+5.2%
양호
My positionMid-range
Low range Average High range
방어주 초소형주 Median 2.1% · Top 40%
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
-27.2%
평균
My positionMid-range
Low range Average High range
방어주 초소형주 Median -4.5% · Bottom 31%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Long-term weakness — -168%p below the market
ENSC -100.0% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-168.3%p
Significantly behind the market
vs Health Care (XLV)
-124.5%p
Significantly behind the sector average
1-year basis
vs S&P 500
-104.3%p
Significantly behind the market
vs Health Care (XLV)
-108.0%p
Significantly behind the sector average
Rank among peers
5-year return Lowest among peers Based on 245 peers
1-year return Bottom 14% Based on 315 peers
Current position within 52-week range
Low (-13.7%p) High (-90.5%p)
Current price is 13.7% above the 52-week low and 90.5% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-60.3%
Annualized volatility
141.7%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴
Current diagnosis · 2026-07-27
Downtrend zone

Current price $0.26 below the midline ($0.28). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🔴
Current diagnosis · 2026-07-27
Bearish momentum holding

MACD -0.006 < Signal -0.005 in negative zone + Hist negative (-0.001). Weakness in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴
Current diagnosis · 2026-07-27
Bearish zone

RSI 41.0 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 28.6.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry
Cheap on Vs. Sales
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
🧾 Vs. Sales Cheap
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
0.85x
✓ Very cheap
My positionTop 5%
Low range Average High range
Biotechnology 초소형주 median 11.24x · Top 1% — relatively cheap within the industry
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
Analyst target price (reference)
$16.45 vs. current price +6226.9%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Biotechnology 초소형주

Who owns it?

Ownership flow is positive
Institutional modest net selling -0.1% · Short interest light 2.6% · Short interest fell -6.4%p over the last 88 days
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
0.0%
Insiders little change
🏦 Institutions (funds & investors)
-0.1%
Institutions net selling
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 3.2%
Retail-led
Healthcare 초소형주 Median 14.2%
🧑‍💼 Insiders 0.1%
Low, common among large-caps
Healthcare 초소형주 Median 16.1%
👤 Retail investors (estimated) 96.8%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
2.6%
Low — limited short-side pressure
Healthcare 초소형주 Median 3.9%
Past 88 days 📉 -6.4%p decrease
Short interest days to cover
0.2 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 15.4M주
Float (tradable shares) 15.4M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 88 days.

ETFs holding ENSC

ETFs with the highest weightings · 1 total shown
* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
ENSC ENSC This Stock
$4.0M- - -870.19% - +0.1%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 엔시스 바이오사이언시스(ENSC)?

엔시스 바이오사이언시스(ENSC) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of ENSC?

The market cap of ENSC is approximately $4M, ranking 5,716 within its sector.

What is the 52-week high and low for ENSC?

ENSC has recorded a 52-week high of $2.75 and a low of $0.23.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.